Our Biosciences team delivers a growing portfolio of biosimilars and specialty injectable products. They deliver value for patients and providers through increased choice, access, and affordability when these highly specialized and typically high-cost medicines are the appropriate option for care.
$18B*
saved by patients in the U.S. in 2022 by using Amneal generics and biosimilar medicines
From 2021 to 2025, Biosimilars are projected to save the U.S. healthcare system, an estimated
$38.4B¹
Courtney Koster
Sr. Director, National Corporate Accounts
Amneal Biosciences is committed to positively impacting the lives of patients living with cancer. Our oncology treatments and supportive-care products are streamlining access for appropriate patients who may need them. We’re also developing evolved formulations of injectable medicines designed to simplify storage and preparation via the 505(b)(2) FDA approval pathway.2,3
“Our ready-to-use injectable presentations are important innovations in oncology, as they reduce the pharmacy preparation steps for clinicians while expanding access to patients.”
— Sean McGowan, Senior Vice President, Biosimilars and Branded Oncology
505(b)(2) regulatory pathway
Learn more about the Amneal Biosciences pipeline
The Amneal PATHways® Patient Support Program is designed to help patients and providers stay on course toward accessible treatment. With its full suite of services and dedicated Program Access Specialists, PATHways allows stakeholders to more easily map a patient’s personal treatment path together.
Learn more
The Amneal PATHways® Patient Support Program provides enrolled patients with a range of resources and services designed to help make their Amneal medicine more accessible and affordable.
Learn more
Corporate
India